GAGohar Azhar

Gohar Azhar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gohar Azhar has a total of 140 co-authors. Here are the top co-authors by number of shared publications:

  • Jeanne Y. Wei

    Department of Geriatrics, Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

    24 shared publications
  • Xiaomin Zhang

    Department of Geriatrics, Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

    15 shared publications
  • Jeanne Y. Wei

    Donald W. Reynolds Institute on Aging, Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

    8 shared publications
  • Ambika Verma

    Donald W. Reynolds Department of Geriatrics and Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

    7 shared publications
  • Pankaj Patyal

    Donald W. Reynolds Department of Geriatrics and Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

    7 shared publications
  • Shakshi Sharma

    Donald W. Reynolds Department of Geriatrics and Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

    5 shared publications

Latest Publications

  • Open Access

    RETRACTED: Abdi et al. Duloxetine, an SNRI, Targets pSTAT3 Signaling: In-Silico, RNA-Seq and In-Vitro Evidence for a Pleiotropic Mechanism of Pain Relief. Int. J. Mol. Sci. 2025, 26, 10432

    by Sayed Aliul Hasan Abdi, Gohar Azhar, Xiaomin Zhang, Jeanne Y. Wei

    The journal retracts the article titled “Duloxetine, an SNRI, Targets pSTAT3 Signaling: In-Silico, RNA-Seq and In-Vitro Evidence for a Pleiotropic Mechanism of Pain Relief”

  • Open Access

    Perceptions of Aging in the Hispanic Community Members in South Central United States: A Descriptive and Exploratory Analysis

    by Ethan Bradford, Basilia Oseguera, Mackenzie Reed, Shakshi Sharma, Lou Ann Eads, Jeanne Wei, Gohar Azhar

    The aim of this study is to investigate perceptions of aging among Hispanic adults. Fifty participants in Texas and Arkansas were asked to take a short questionnaire including multiple‐choice and Likert scale format questions. Individuals 18 and older who identified as Hispanic were included in the study. Counts and frequencies for each response were obtained. Furthermore, an exploratory comparison of responses between younger and middle‐aged/older respondents was conducted. According to the results of the study, the Hispanic adults surveyed were found to have a generally positive view of aging, most frequently associating older age with the words “Wisdom” (68%) and “Experience” (12%). However, respondents still had anxieties about aging, with many answering that they feared death (41.3%), loss of independence (41.7%), and financial issues (31.3%) often or always. Additionally, the majority of those surveyed indicated that they would prefer to live with their spouse only in old age, which may reflect a generational difference in attitudes toward living arrangements. Keeping these results in mind will be essential for healthcare providers as they aim to develop culturally competent educational programs to relieve caregiver burden and support healthy aging for the rapidly growing older Hispanic population in the United States.

  • Open Access

    RETRACTED: Duloxetine, an SNRI, Targets pSTAT3 Signaling: In-Silico, RNA-Seq and In-Vitro Evidence for a Pleiotropic Mechanism of Pain Relief

    by Sayed Aliul Hasan Abdi, Gohar Azhar, Xiaomin Zhang, Jeanne Y. Wei

    Chronic pain is a serious health issue, often irrationally managed by conventional analgesics. Duloxetine, a serotonin–norepinephrine reuptake inhibitor (SNRI), also effective in neuropathic and musculoskeletal pain, but the molecular mechanism of its analgesic action is still unclear. Here, we examined whether Duloxetine exerts pleiotropic effects by directly targeting phosphorylated STAT3 (pSTAT3), a key regulator of neuroinflammation and pain sensitization. Molecular docking showed that Duloxetine binds with pSTAT3 with binding energy −5.83 kcal/mol. Ruxolitinib, a JAK/STAT inhibitor used as reference, showed binding energy of −6.19 kcal/mol. Molecular dynamics (MD) simulations confirmed stable Duloxetine–pSTAT3 complexes, while MM-PBSA free energy analysis revealed more favorable binding for Duloxetine (ΔG = −15.17 kJ·mol−1) than Ruxolitinib (ΔG = −12.98 kJ·mol−1) for pSTAT3. In-vitro analyses, Western blot showed that Duloxetine significantly reduced IL-6–induced STAT3 and pSTAT3 expression in C2C12 cells in a dose-dependent manner (6.4 and 12.8 μM, *** p < 0.0001), although Ruxolitinib produced a stronger suppression. Transcriptomic analysis revealed Duloxetine-specific enrichment of mitochondrial, oxidative phosphorylation, and synaptic pathways, distinct from the immune-suppressive influence of Ruxolitinib. RNA-seq further revealed that STAT3 transcript abundance remains constant under all treatment conditions, indicating that post-transcriptional or post-translational mechanisms, such as phosphorylation-dependent activation, may be involved rather than transcriptional modulation of STAT3 in action of Ruxolitinib and Duloxetine and the formation of novel STAT3 indicating enhanced transcript diversity. The rMATS splicing analysis confirmed dose-dependent modulation, with Duloxetine promoting mild exon skipping at 6.4 μM (IncLevel 0.90 → 0.80) and recovery at 12.8 μM (0.85 → 0.86), while Ruxolitinib induced stronger exon inclusion (0.85 → 1.00,0.94), with broader transcript suppression at 6.4 μM and 12.8 μM, respectively. These findings establish Duloxetine as a dual-action therapeutic that combines neurotransmitter reuptake inhibition with pSTAT3 suppression and isoform-level transcriptomic modulation. This pleiotropic mechanism provides a rationale for its durable analgesic effects and supports repurposing in STAT3-associated disorders.


  • Open Access

    Mitochondrial Dynamics in Aging Heart

    by Pankaj Patyal, Gohar Azhar, Ambika Verma, Shakshi Sharma, Jyotsna Shrivastava, Sayed Aliul Hasan Abdi, Xiaomin Zhang, Jeanne Y. Wei

    Aging is a major risk factor for cardiovascular disease, driving progressive structural and functional decline of the myocardium. Mitochondria, the primary source of ATP through oxidative phosphorylation, are essential for cardiac contractility, calcium homeostasis, and redox balance. In the aging heart, mitochondria show morphological alterations including cristae disorganization, swelling, and fragmentation, along with reduced OXPHOS efficiency. These defects increase proton leak, lower ATP production, and elevate reactive oxygen species (ROS), causing oxidative damage. Concurrent disruptions in mitochondrial fusion and fission further impair turnover and quality control, exacerbating mitochondrial dysfunction and cardiac decline. Serum response factor (SRF) signaling, a crucial regulator of cytoskeletal and metabolic gene expression, plays a key role in modulating mitochondrial function during cardiac aging. Dysregulation of SRF impairs mitochondrial adaptability, contributing to dysfunction. Additionally, reduced levels of nicotinamide adenine dinucleotide (NAD+) hinder sirtuin-dependent deacetylation, further compromising mitochondrial efficiency and stress resilience. These cumulative defects activate regulated cell death pathways, leading to cardiomyocyte loss, fibrosis, and impaired diastolic function. Mitochondrial dysfunction therefore serves as both a driver and amplifier of cardiac aging, accelerating the transition toward heart failure. This narrative review aims to provide a comprehensive overview of mitochondrial remodeling in the aging myocardium, examining the mechanistic links between mitochondrial dysfunction and myocardial injury. We also discuss emerging therapeutic strategies targeting mitochondrial bioenergetics and quality control as promising approaches to preserve cardiac function and extend cardiovascular health span in the aging population.


  • Open Access

    Differential microRNA profiling of the Marshallese population in Arkansas reveals a higher association with chronic diseases

    by Gohar Azhar, Ambika Verma, Pankaj Patyal, Wei Zhang, Shakshi Sharma, Patricia E. Savary, Sheldon Riklon, Philmar Mendoza Kabua, Pearl A. McElfish, Jeanne Y. Wei

    The Marshallese communities face disproportionately high prevalence of chronic diseases, including diabetes, obesity, cardiovascular disease, and inflammatory conditions. Differences in miRNA expression may contribute to investigate the potential risk of chronic diseases in Marshallese people. In this study, we used RNA isolated from blood samples of Marshallese participants that resides in Arkansas to perform miRNA expression profiling and differential expression analysis. Specifically, blood samples were collected from 47 Marshallese participants after obtaining written informed consent and were subjected to Illumina-based next-generation RNA sequencing. Using the miRBase database, we identified the miRNAs that were most significantly expressed based on log2 fold change values, applying a Bonferroni-corrected P-value threshold of < 0.01. We found that a total of 63 human miRNAs were differentially expressed in the Marshallese subjects, with 52 miRNAs significantly upregulated and 11 miRNAs downregulated in males compared with females. Notably, 2 miRNA families, hsa-miR-548 and hsa-let-7, were significantly upregulated in the Marshallese population and are known to play important roles in regulating inflammatory responses. Further analysis revealed the 25 miRNAs that had the largest significant difference in expression with a cutoff of 1.5 when comparing males with females. Among these, we observed that 7 miRNAs were upregulated, and 18 miRNAs were downregulated by greater than 1.5 log2 fold change in males versus females. Interestingly, upregulated expression of hsa-miR-548k in males and hsa-miR-496 in females were both associated with diabetes mellitus. Diabetes remains a major health concern in the Marshallese community and may accelerate comorbidities related to cardiovascular conditions and cognitive decline. Therefore, the specific roles of these miRNAs in relation to these health issues warrant further investigation.


  • Open Access

    Alternative Splicing of Serum Response Factor Reveals Isoform-Specific Remodeling in Cardiac Diseases

    by Sayed Aliul Hasan Abdi, Gohar Azhar, Xiaomin Zhang, Shakshi Sharma, Mohib Hafeez, Jeanne Y. Wei

    Background: Alternative splicing is an important mechanism of transcriptomic and proteomic diversity and is progressively involved in cardiovascular disease (CVD) pathogenesis. Serum response factor (SRF), a critical transcription factor in cardiac development and function, may itself undergo splicing regulation, potentially altering its function in disease states. Objective: The objective of this study is to identify SRF-associated alternative splicing events in cardiac pathological conditions and examine regulatory interactions with splicing factors using RNA-seq data. Methods: Three human heart RNA-seq databases (PRJNA198165, PRJNA477855, PRJNA678360) were used, comprising various cardiac conditions like non-ischemic cardiomyopathy (NICM), ischemic cardiomyopathy (ICM), dilated cardiomyopathy (DCM), and heart failure with reduced ejection fraction (HFrEF), with and without left ventricular assist device (LVAD) support. Splicing events were identified using the rMATS tool, and correlation analyses were performed between SRF and predicted splicing factors. Functional enrichment of SRF-correlated genes was assessed via Gene Ontology (GO) and KEGG pathways. Results: The skipped exon (SE) events were the predominant splicing type across all datasets. SRF chr6, including (Exon 2, 43,173,847–43,174,113), (Exon 4, 43,176,548–43,176,667), and (Exon 5, 43,178,294-43,178,485), were most frequently involved in SE and mutually exclusive exon (MXE) events across multiple heart failure subtypes. Correlation analysis revealed strong positive associations between SRF and several splicing factors (HNRNPL, HNRNPD, SRSF5, and SRSF8). GO and KEGG analyses revealed enrichment of muscle development, sarcomere structure, lipid metabolism, and immune signaling pathways. Conclusions: Our study shows that SRF is subject to extensive alternative splicing in heart failure, particularly at Exon 2 and Exon 5, suggesting isoform-specific roles in cardiac remodeling. The strong co-expression with specific splicing factors delineates a regulatory axis that may explain the pathological transcriptome in cardiomyopathy. These findings provide a foundation for exploring splicing-based biomarkers and therapeutic targets in cardiac pathology for SRF.


  • Open Access

    Porphyromonas gingivalis-Lipopolysaccharide Induced Caspase-4 Dependent Noncanonical Inflammasome Activation Drives Alzheimer’s Disease Pathologies

    by Ambika Verma, Gohar Azhar, Pankaj Patyal, Xiaomin Zhang, Jeanne Y. Wei

    Chronic periodontitis, driven by the keystone pathogen Porphyromonas gingivalis, has been increasingly associated with Alzheimer’s disease (AD) and AD-related dementias (ADRDs). However, the mechanisms through which P. gingivalis-lipopolysaccharide (LPS)-induced release of neuroinflammatory proteins contribute to the pathogenesis of AD and ADRD remain inadequately understood. Caspase-4, a critical mediator of neuroinflammation, plays a pivotal role in these processes following exposure to P. gingivalis-LPS. In this study, we investigated the mechanistic role of caspase-4 in P. gingivalis-LPS-induced IL-1β production, neuroinflammation, oxidative stress, and mitochondrial alterations in human neuronal and microglial cell lines. Silencing of caspase-4 significantly attenuated IL-1β secretion by inhibiting the activation of the caspase-4-NLRP3-caspase-1-gasdermin D inflammasome pathway, confirming its role in neuroinflammation. Moreover, caspase-4 silencing reduced the activation of amyloid precursor protein and presenilin-1, as well as the secretion of amyloid-β peptides, suggesting a role for caspase-4 in amyloidogenesis. Caspase-4 inhibition also restored the expression of key neuroinflammatory markers, such as total tau, VEGF, TGF, and IL-6, highlighting its central role in regulating neuroinflammatory processes. Furthermore, caspase-4 modulated oxidative stress by regulating reactive oxygen species production and reducing oxidative stress markers like inducible nitric oxide synthase and 4-hydroxynonenal. Additionally, caspase-4 influenced mitochondrial membrane potential, mitochondrial biogenesis, fission, fusion, mitochondrial respiration, and ATP production, all of which were impaired by P. gingivalis-LPS but restored with caspase-4 inhibition. These findings provide novel insights into the role of caspase-4 in P. gingivalis-LPS-induced neuroinflammation, oxidative stress, and mitochondrial dysfunction, demonstrating caspase-4 as a potential therapeutic target for neurodegenerative conditions associated with AD and related dementias.


  • Open Access

    Effect of Protein Supplementation on Orthostatic Hypotension in Older Adult Patients with Heart Failure

    by Gohar Azhar, Amanda K. Pangle, Karen Coker, Shakshi Sharma, Jeanne Y. Wei

    Purpose: Heart failure (HF) impairs physical performance and increases the incidence of orthostatic hypotension (OH). Individuals with OH have a higher risk of falls, which are a major source of morbidity and mortality in older adults. Dietary protein supplementation can improve physical performance in healthy older adult individuals; however, its effect on OH in older adult patients with HF is unknown. Methods: Twenty-one older adult patients with mild-to-moderate HF were randomized to placebo or protein supplementation. Dietary protein was supplemented with whey protein so the total protein intake for each participant was 1.2 g/kg bodyweight/day, plus 1 g/day of the amino acid l-carnitine for 16 weeks. Susceptibility to OH was assessed using a head-up tilt test, blood markers, and a functional test (6 min walk) at baseline and 16 weeks. Results: There were no differences in tilt test responses or 6 min walk test (6MWT) distances. The protein-supplement group had a significant increase in 6MWT pulse pressures post-walk after 16 weeks of treatment as compared to placebo. However, the tachycardia observed at baseline after 6MWT in the protein group was not seen at the end of the study. There was also a trend towards lower levels of brain naturetic peptide (proBNP) in the protein group vs. placebo at 16 weeks. Conclusions: The improved pulse-pressure response to exertion and positive trends in proBNP in this pilot study suggest that dietary supplementation may improve cardiovascular function and general health in individuals with HF and that larger future studies are justifiable.


  • Open Access

    The Long-Term Cardiovascular Risks of Duloxetine Use in Older Adults: A Retrospective Medical Record-Based Adverse Drug Reaction Assessment

    by Yuqi Cui, Sayed Aliul Hasan Abdi, Jeanne Wei, Gohar Azhar

    Background: Duloxetine, a Serotonin–Norepinephrine Reuptake Inhibitor (SNRI), is frequently used to treat diabetic peripheral neuropathy, depression, and fibromyalgia. However, its long-term cardiovascular implications in older individuals remain underexplored, particularly in those with pre-existing cardiovascular diseases. This medical record assessment aimed to evaluate the potential cardiovascular risks of duloxetine use in older persons after prolonged use. Methods: We evaluated adverse drug reactions (ADRs) using six medical records from elderly individuals (aged 70–79) with cardiovascular comorbidities who received duloxetine (≥60 mg daily) for anxiety, depression, and chronic pain. ADRs were assessed using the Naranjo ADR Probability Scale, the Modified Hartwig and Siegel Severity Scale, and the Karch and Lasagna Algorithm. Clinical outcomes were assessed before and after duloxetine dose reduction or withdrawal. Results: All the patients had cardiovascular-related ADRs, such as peripheral cyanosis, vasoconstriction, atrial fibrillation, and hypertensive episodes. Five of the six patients experienced mild cognitive impairment [Montreal Cognitive Assessment (MoCA) scores of 11–24/30]. A positive dechallenge (symptom resolution) was observed in all medical records after decreasing or discontinuing duloxetine. It is interesting to note that four medical records demonstrated significant improvement in cyanosis, blood pressure, and anxiety after decreasing or discontinuing duloxetine use. There was no rechallenge in this study. The causality was considered probable (Naranjo Scale), and ADRs were categorized as moderately severe (Hartwig and Siegel Scale) in all the medical records. However, with adequate monitoring, the ADRs were considered preventable (Schumock and Thornton Scale). Conclusions: Long-term duloxetine use could cause significant cardiovascular problems in older individuals, particularly those who already have cardiovascular difficulties. Regular monitoring of cardiovascular function and early steps such as dose adjustment or drug withdrawal of duloxetine may reduce the prognosis of ADRs. More studies are required to create safer treatment strategies for managing depression and anxiety in older people with cardiovascular issues.


  • Open Access

    Missed Insights for Earlier Management of Parkinson’s Disease and the Value of Dopamine Transporter (DAT) Scans

    by Mohib Hafeez, Elizabeth Eoff, Jeanne Wei, Gohar Azhar

    Background/Objectives: This retrospective study focused on the role of Dopamine Transporter (DAT) scans in diagnosing Parkinson’s Disease (PD) in older adults with cognitive impairment (CI). Methods: We retrospectively analyzed brain imaging of 6483 individuals aged 60 and above with CI. Among these, 297 underwent a DAT scan, with 189 testing positive and 89 starting dopamine therapy. In contrast, 173 patients exhibited PD-associated structural changes on CT or MRI without receiving DAT scans or treatment. Results: Of these patients, 50 (29%) experienced falls. This points towards a potential missed diagnosis of PD, which can respond to therapy in the early stages. Conclusions: Our results suggest that providers may overlook subtle signs of parkinsonism in patients with CI, resulting in symptoms worsening and treatment delay. Since CI is often first brought to the attention of PCPs, our findings call for an increased effort to inform PCPs of the role of DAT scans in aiding the diagnosis of dopamine deficiency states. By understanding PD-related structural changes seen on brain imaging and using a DAT scan to confirm dopamine deficiency, treatment for PD or related states might be started earlier or a timely referral made to a specialist, reducing patient disability and improving their quality of life.